German and US firms pool orthopaedic technology:
This article was originally published in Clinica
US company Orquest has linked with Biopharm, of Heidelberg, Germany, to pool proprietary technologies. The German company will contribute MP52, a novel recombinant growth factor bone morphologic protein, while Mountain View, California-based Orquest will put in "unique proprietary materials and know-how for developing and assembling combinations of growth factors and matrices". The first product is expected to be HealosMP52 for spinal fusion, which is being developed with Sulzer SpineTech and is about to enter clinical trials in the US and Europe.
You may also be interested in...
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.